(IFRX) InflaRx N.V. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IFRX) InflaRx N.V. Complete Analysis Pack
See the Bigger Picture
This InflaRx N.V. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page includes a real preview/sample so you can evaluate style and content before buying. Purchase the full version to receive the complete, ready-to-use analysis for strategy, benchmarking, or presentations.
Product
Vilobelimab, first-in-class anti-C5a mAb
Vilobelimab is InflaRx N.V.’s lead asset and the core of its pipeline. This first-in-class anti-C5a monoclonal antibody is designed to block C5a, a key driver of inflammation, and is given intravenously. In 2025, InflaRx reported R&D spending of €22.5 million, underscoring how central Vilobelimab remains to product investment.
Hidradenitis suppurativa, Phase III completed
Vilobelimab has completed Phase III in hidradenitis suppurativa, a rare, chronic, painful inflammatory skin disease, making it InflaRx N.V.'s most advanced pipeline asset. In HS, published estimates put prevalence around 0.1% to 1%, and a successful launch could target a small but high-need specialty market with limited approved options.
AAV, Phase II ongoing
InflaRx N.V.'s AAV candidate is in Phase II testing in anti-neutrophil cytoplasm antibody-associated vasculitis, a rare autoimmune disease that affects about 30 to 40 people per million in Europe each year and can cause organ failure. That focus fits the company’s push into severe inflammatory disorders with high unmet need. In a small patient pool, clinical proof of benefit matters more than broad volume.
CSCC, Phase II ongoing
Vilobelimab is in Phase II for PD-1 and PD-L1 inhibitor resistant or refractory locally advanced or metastatic cutaneous squamous cell carcinoma, keeping InflaRx N.V. in a narrow, high-need oncology-inflammation niche. Phase II means the product is still proving signal, dose, and safety before any larger readout.
This is a specialty indication, not a broad-market one, so the value case depends on strong response data in a small, hard-to-treat patient pool. In 2025, the main commercial lever is clinical differentiation, not volume.
- Phase II, ongoing
- PD-1 and PD-L1 resistant cSCC
- Specialized oncology-inflammation use
- Clinical proof drives value
INF904 oral; IFX002 preclinical
InflaRx N.V. broadens its pipeline with INF904, a second drug candidate given as an oral small molecule, and IFX002, a preclinical program for chronic inflammation and autoimmune disease. These two assets reduce reliance on vilobelimab and give the Company Name more shots at value creation across different stages of development. One is clinical-stage oral convenience; the other is an early-stage inflammation bet.
- INF904: oral small molecule
- IFX002: preclinical program
- Focus: chronic inflammation and autoimmunity
- Mix: beyond vilobelimab
InflaRx’s Pipeline Stays Focused on Vilobelimab and Growth
InflaRx N.V.’s Product mix is still centered on vilobelimab, a Phase III anti-C5a antibody for hidradenitis suppurativa and Phase II cSCC. The pipeline also includes INF904, an oral small molecule, and IFX002, a preclinical asset. In 2025, R&D spending was €22.5 million, showing continued product focus.
| Asset | Status | Use |
|---|---|---|
| Vilobelimab | Phase III / II | HS, cSCC |
| INF904 | Clinical | Oral inflammation |
| IFX002 | Preclinical | Autoimmune |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P's analysis of InflaRx N.V.’s marketing strategy, covering product, price, place, and promotion with real-world context.
Editable Excel File
Condenses InflaRx N.V.’s 4Ps into a quick, clear snapshot, easing fast review and strategic alignment.
Reference Sources
Provides a concise, traceable bibliography of primary industry reports, regulatory filings, and peer-reviewed data to speed due diligence and validate InflaRx assumptions.
Place
Jena, Germany headquarters
InflaRx N.V. is headquartered in Jena, Germany, its main corporate base. The site anchors administration, research oversight, and strategic coordination for a company that reported cash and cash equivalents of $54.7 million at year-end 2025. That base supports day-to-day control of its clinical and operating work.
Operations in the United States
InflaRx N.V. also operates in the United States, extending its footprint beyond Germany and supporting clinical, regulatory, and business development work. That U.S. base matters because U.S. FDA engagement is critical for drug development, and the company’s lead asset, vilobelimab, has been advanced through U.S.-linked clinical work. In 2025, InflaRx N.V. reported no product revenue and continued to rely on cash resources to fund operations.
Clinical trial site distribution
For InflaRx N.V., clinical trial site distribution is the core access point, not retail channels, because vilobelimab, INF904, and IFX002 move through hospital and investigator sites under protocol control. Trial materials are shipped directly to study centers, which keeps dosing, safety checks, and data capture tightly managed across clinical-stage programs. This model fits a biotech with no commercial launch yet, so site coverage drives patient reach and enrollment speed.
Co-development with Beijing Defengrei
InflaRx N.V.'s co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. gives it a partner-led route into broader regional development. It also signals planned China-linked development activity, which can lower local execution risk versus a solo push.
- Partner-based regional expansion
- China-linked development presence
- Shared local execution capacity
Supply collaboration with Merck
InflaRx N.V. has a clinical trial collaboration and supply agreement with Merck & Co., Inc., which gives it access to study supply and helps run trials on time. This is a development channel, not a commercial sales route. It matters most for clinical execution because it reduces supply and logistics risk in late-stage studies.
- Merck supports study supply access.
- Used for clinical development, not sales.
- Helps trial execution and continuity.
InflaRx’s Market Access Is Trial-Driven, Not Sales-Led
InflaRx N.V. uses Jena, Germany, as its main operating base, with U.S. presence for clinical and regulatory work. In 2025, it held $54.7 million in cash and cash equivalents, so its place strategy stays centered on funded trial execution, not sales coverage. Its real market access points are hospital and investigator sites for vilobelimab, INF904, and IFX002, plus partner-led routes in China and trial support through Merck.
Preview the Actual Deliverable
InflaRx N.V. Reference Sources
The preview shown here is the actual InflaRx N.V. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.
This is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use.
You’re viewing the exact version of the analysis included in your order; buy with full confidence.
Promotion
Clinical trial milestones
InflaRx N.V. uses clinical trial milestones as a core promotion tool, highlighting phase progress to signal pipeline strength. Its phase III hidradenitis suppurativa program and ongoing phase II and phase IIa studies show active clinical depth, which supports scientific credibility and investor interest. Clear readouts and updates help turn trial progress into measurable pipeline value.
Scientific and medical communications
InflaRx N.V.’s promotion is aimed mainly at physicians, researchers, and investors, with conference posters and medical data disclosures doing the heavy lifting. In biotech, these channels explain mechanism, safety, and efficacy fast, which matters when one clinical readout can re-rate a stock; InflaRx’s vilobelimab program has been reported across major immunology and dermatology meetings.
Investor relations disclosure
InflaRx N.V. leans on investor relations disclosure as a core promotion tool, using earnings releases, annual reports, and corporate presentations to keep investors updated on trial progress and funding needs. For a clinical-stage company with no product revenue, these updates are one of the main ways to build credibility and support the share price.
Partnership announcements
Merck and Beijing Defengrei partnerships do more than support InflaRx N.V.'s pipeline; they act as promotional proof points. Two external alliances signal shared development skill and raise trust with partners, investors, and clinicians. In biotech, that kind of validation can matter as much as cash.
- 2 named collaborations boost credibility
- Signal external validation
- Support market awareness and trust
Regulatory and trial registry visibility
Clinical trial registrations and regulatory filings make InflaRx N.V.'s pipeline public. ClinicalTrials.gov holds 500,000+ studies, and many U.S. interventional trials must be posted within 21 days of first enrollment, so rare-disease and oncology work stays visible to clinicians, investors, and partners.
- Low-cost public promotion
- Signals pipeline progress
- Supports partner outreach
InflaRx’s 2025–2026 Growth Signal: Trials, Partnerships, and Data
InflaRx N.V. promotes itself mainly through clinical data, conference updates, and investor disclosures, since it has no product sales. Its 2025–2026 value signal comes from vilobelimab’s phase III hidradenitis suppurativa work and phase II/IIa studies, plus named alliances with Merck and Beijing Defengrei. Trial registrations also keep the pipeline visible to clinicians and investors.
| Promotion lever | Signal | 2025–2026 data |
|---|---|---|
| Clinical milestones | Pipeline strength | Phase III, II, IIa |
| Partnerships | External validation | 2 named collaborations |
| Public filings | Low-cost visibility | ClinicalTrials.gov 500,000+ studies |
Price
No marketed product price disclosed
InflaRx N.V. has no marketed product price disclosed because it remains a clinical-stage company. As of the latest public filings, pricing is not publicly set for vilobelimab, INF904, or IFX002, and there are no commercial sales to anchor list pricing. That means any future price will depend on trial results, regulatory approval, and payer talks.
Precommercial pricing stage
InflaRx N.V.'s lead asset is still in development, so price is not yet a customer-facing lever; there are 0 commercial sales today. Any future price will hinge on FDA/EMA approval, label breadth, and payer reimbursement, which is standard for biotech before launch. In this stage, value is built on clinical data, not list price.
Rare disease premium potential
InflaRx N.V.'s lead targets are rare, severe diseases: hidradenitis suppurativa affects about 1% to 4% of people, and AAV incidence is roughly 10 to 20 cases per million each year. That kind of niche often supports premium biologic pricing if clinical benefit is clear, but payers will still push back hard on total value and durability.
Hospital-administered biologic economics
Vilobelimab is an IV monoclonal antibody, so pricing would be tied to hospital and infusion-center economics, not retail shelf price. In 2025, InflaRx reported vilobelimab was still a hospital-administered asset, so site-of-care fees, chair time, and nursing use matter. This usually lifts total treatment cost well above drug-only price.
Hospital billing will include administration costs.
Infusion-center site-of-care drives economics.
Not an OTC or pharmacy-retail model.
Partner-funded development economics
InflaRx N.V.'s partner-funded development model can blunt cash outlay: the Merck and Beijing Defengrei deals may share R&D costs before launch, which can ease pressure on the company’s own balance sheet and support more flexible pricing later. In 2025, this matters because lower net spend can help preserve cash for C5a pipeline work.
- Cost sharing lowers InflaRx N.V.'s upfront burden.
- Partner payments can offset development risk.
- Pricing power may rise after shared pre-launch costs.
InflaRx Pricing Hinges on Approval, Coverage, and Rare-Disease Demand
Price is not set yet because InflaRx N.V. has no marketed product and no commercial sales in 2025. Future pricing for vilobelimab will depend on FDA/EMA approval, payer coverage, and site-of-care costs for IV dosing. For rare diseases like hidradenitis suppurativa and AAV, premium pricing is possible if clinical benefit is clear.
| Metric | Value |
|---|---|
| Commercial sales | 0 |
| Vilobelimab price | Not disclosed |
| HS prevalence | 1% to 4% |
| AAV incidence | 10 to 20 per million/year |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.